REGNRegeneron PharmaceuticalsNot started yet
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
Diffuse Large B-Cell Lymphoma (DLBCL)
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 1/2
- Patients
- 36 (planned)
- Started
- Dec 7, 2026
- Main results expected
- Nov 1, 2029
- Fully finished
- Nov 1, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Occurrence of Dose-Limiting Toxicities (DLTs) during the DLT observation period
Measured over: Up to 28 days
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Measured over: Up to approximately 2 years
Severity of TEAEs
Measured over: Up to approximately 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07887750 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC